2023 World Conference on Lung Cancer (Posters)-EP13.02. Entrectinib Amazing Efficacy in a Case of Lung Atypical Carcinoid with NTRK Gene Fusion

Pdf Summary

This case report highlights the efficacy of entrectinib, a selective NTRK kinase inhibitor, in a patient with lung atypical carcinoid with NTRK gene fusion. The patient, a 56-year-old woman, initially presented with cough and expectoration and was diagnosed with lung atypical carcinoid in July 2020. Despite undergoing multiple lines of therapy including chemotherapy, radiotherapy, and targeted therapy, the patient experienced disease progression with bone and brain metastases. <br /><br />In February 2023, a re-biopsy revealed the presence of ETV6-NTRK2 gene fusion. Following this finding, the patient was treated with entrectinib at a dose of 600 mg once daily. After just one month of treatment, the patient achieved a complete response, with the disappearance of the left pleural tumor and the right chest wall subcutaneous mass. Tumor markers also returned to normal levels.<br /><br />This case is particularly significant because NTRK gene fusions are rare oncogenic drivers found in various tumor types, including non-small cell lung cancer. However, they only account for a small percentage of targetable oncogenic driver molecular alterations in NSCLC. Entrectinib is a selective inhibitor approved by the FDA for the treatment of advanced NTRK gene fusion-positive solid tumors.<br /><br />The efficacy of entrectinib in this case emphasizes the potential of this targeted therapy for the treatment of rare neuroendocrine tumors with NTRK fusion. The patient in this case had previously failed multiple lines of therapy, including platinum-based chemotherapy and immunotherapy, highlighting the successful use of entrectinib as the seventh line of therapy.<br /><br />This case report underscores the importance of identifying specific molecular alterations, such as NTRK gene fusions, in guiding treatment decisions and selecting appropriate targeted therapies. Entrectinib, as a selective NTRK kinase inhibitor, offers promise in the treatment of rare neuroendocrine tumors with NTRK fusion, providing a potential therapeutic option for patients who have failed other lines of therapy.

Asset Subtitle

Hui Shi

Meta Tag

Speaker Hui Shi

Topic SCLC & Neuroendocrine Tumors: Case Report

Keywords

entrectinib

NTRK gene fusion

lung atypical carcinoid

efficacy

selective kinase inhibitor

targeted therapy

disease progression

metastases

complete response

tumor markers